The DRIVE-AB consortium: a step towards sustainable antibiotic development

In a new report issued by the University of Geneva (Switzerland) and AstraZeneca (Cambridge, UK), research-based suggestions are provided for the development of a new economic model to promote antibiotic innovation and sustainable use.

The urgent need for new antibiotics to treat resistant infections in only increasing, however, the use of newly-developed antibiotics must also be restricted to minimize further occurrences of resistance. This has led to concerns over lower investment returns than most other medical fields, which is why DRIVE-AB was established to recommend newer economic models to provide industry with an incentive to invest.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment